世卫组织总干事谭德塞:中国医改成效大 建议积极研发新药

2018-07-18 佚名 央视新闻

世卫组织总干事谭德塞认为,中国医改在短时间内取得了显著的成效令人振奋,但应更加注重医疗资源的均衡性和公平性。

世卫组织总干事谭德塞于7月16日至18日对中国进行了访问,央视记者昨晚(17日)对谭德塞进行了采访。他认为,中国医改在短时间内取得了显着的成效令人振奋,但应更加注重医疗资源的均衡性和公平性。

世卫组织总干事谭德塞:中国医改成效大 需注重资源均衡

谭德塞表示,中国新一轮的医改从2009年启动至今,已经有超过13.5亿人享受到基本医疗保险,参保率超过95%。这是由于中国政府把全民健康覆盖作为了一项终极目标。

世界卫生组织总干事 谭德塞:中国的经验可以被其他国家借鉴,它证明了全民健康覆盖是一个政治选择。只有把它作为一项政治承诺,才能真正取得效果。

谭德塞同时表示,中国卫生服务体系的均衡性仍然有待提高,在部分经济发达地区,医疗费用自费比例已经降低至17%,接近世卫组织的建议目标,但在一些不发达地区这一数值仍然高达30%。中国政府制定的健康中国2030规划纲要,提供了一个很好的机会,可以补齐这个短板,更好地实现健康公平性。

谭德塞:所以中国政府在这一纲要下,应该增加公平性,将卫生服务更多地推广至农村地区。

谭德塞:“一带一路”促进沿线国家卫生合作

2017年中国与世卫组织签署了“一带一路”卫生合作备忘录。世卫组织总干事谭德塞表示,“一带一路”倡议对世界各国卫生健康领域的发展是一大契机,符合全民健康覆盖的目标,世卫组织支持在“一带一路”倡议下对沿线各国卫生领域发展进行投资。

谭德塞表示,“一带一路”倡议目标宏大,它覆盖了60多个具有潜力的国家、占全世界GDP总量的30%。其中包括公共卫生水平较低而使得整体经济增长潜力受限的世卫组织会员国。“一带一路”倡议会给沿线各国带来建设和就业,改善沿线各国公众的营养和健康水平,同时也将全球卫生合作与经济发展相结合,世卫组织期待着与“一带一路”沿线会员国合作,设法将卫生健康融入各国经济发展战略与决策,增强卫生服务提供能力和疾病防控能力,在未来五年实现“三个十亿”目标,即全民健康覆盖受益人口新增十亿人,面对突发卫生事件受到更好保护的人口增加十亿人,健康福祉得到改善的人口新增十亿人。

谭德塞:我们会继续支持“一带一路”倡议,因为它会促进实现世界全民健康覆盖以及联合国可持续发展目标。

谭德塞:鼓励中国生产仿制药及研发新药

近期我国抗癌药话题引发热议,让更多目光投向这一关乎生命健康的市场。世卫组织总干事谭德塞表示,中国应该一方面在国际规则允许的前提下增加仿制药的生产,解决公众用药的燃眉之急,另一方面积极加强新药的研发。

谭德塞:我实际上建议中国应该两条腿走路,积极研发新的原研药,但同时也应该仿制一些药。当然,中国非常熟悉国际规则。今天(17日)我在跟中国负责药监的部门会谈当中提到,要支持和鼓励中国进一步提升国产药品的质量,不仅是原研药也包括仿制药,不仅是提高质量用于国内需求,同时也要让中国药品进入国际市场。

谭德塞:刚果民主共和国埃博拉疫情得到控制

此外,世卫组织总干事谭德塞昨天还介绍,今年5月,刚果民主共和国再次出现埃博拉疫情,疫情在7月6日得到控制,截至目前未发现新的疫情。如果到7月24日前未再发现新病例,将宣布刚果民主共和国脱离埃博拉疫情。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011696, encodeId=4fee2011696e8, content=<a href='/topic/show?id=97ed21e3449' target=_blank style='color:#2F92EE;'>#中国医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21734, encryptionId=97ed21e3449, topicName=中国医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Mon Feb 18 04:05:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287015, encodeId=5c5b128e01526, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300172, encodeId=da8113001e268, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300840, encodeId=d0d7130084031, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332509, encodeId=8db8332509b0, content=医改成效大国人一直在努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jul 18 17:19:49 CST 2018, time=2018-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011696, encodeId=4fee2011696e8, content=<a href='/topic/show?id=97ed21e3449' target=_blank style='color:#2F92EE;'>#中国医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21734, encryptionId=97ed21e3449, topicName=中国医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Mon Feb 18 04:05:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287015, encodeId=5c5b128e01526, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300172, encodeId=da8113001e268, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300840, encodeId=d0d7130084031, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332509, encodeId=8db8332509b0, content=医改成效大国人一直在努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jul 18 17:19:49 CST 2018, time=2018-07-18, status=1, ipAttribution=)]
    2018-07-20 tidiq
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011696, encodeId=4fee2011696e8, content=<a href='/topic/show?id=97ed21e3449' target=_blank style='color:#2F92EE;'>#中国医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21734, encryptionId=97ed21e3449, topicName=中国医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Mon Feb 18 04:05:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287015, encodeId=5c5b128e01526, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300172, encodeId=da8113001e268, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300840, encodeId=d0d7130084031, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332509, encodeId=8db8332509b0, content=医改成效大国人一直在努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jul 18 17:19:49 CST 2018, time=2018-07-18, status=1, ipAttribution=)]
    2018-07-20 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011696, encodeId=4fee2011696e8, content=<a href='/topic/show?id=97ed21e3449' target=_blank style='color:#2F92EE;'>#中国医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21734, encryptionId=97ed21e3449, topicName=中国医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Mon Feb 18 04:05:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287015, encodeId=5c5b128e01526, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300172, encodeId=da8113001e268, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300840, encodeId=d0d7130084031, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332509, encodeId=8db8332509b0, content=医改成效大国人一直在努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jul 18 17:19:49 CST 2018, time=2018-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2011696, encodeId=4fee2011696e8, content=<a href='/topic/show?id=97ed21e3449' target=_blank style='color:#2F92EE;'>#中国医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21734, encryptionId=97ed21e3449, topicName=中国医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Mon Feb 18 04:05:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287015, encodeId=5c5b128e01526, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300172, encodeId=da8113001e268, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300840, encodeId=d0d7130084031, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 20 08:05:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=332509, encodeId=8db8332509b0, content=医改成效大国人一直在努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jul 18 17:19:49 CST 2018, time=2018-07-18, status=1, ipAttribution=)]
    2018-07-18 1e0f8808m18(暂无匿称)

    医改成效大国人一直在努力

    0

相关资讯

世界卫生大会开幕 公布“3个10亿”健康目标

世界卫生大会当天公布一份工作总体规划,用于指导世卫组织2019年至2023年的工作。

世卫组织启动促进身体活动全球行动计划:规律运动是防治心脏病的关键手段之一

近日,世卫组织总干事谭德塞博士与葡萄牙总理安东尼奥·科斯塔一道发布新了《世卫组织2018-2030年促进身体活动全球行动计划:加强身体活动,造就健康世界》。

Lancet:世界卫生组织呼吁,国家元首对慢病防治负主要责任,而不是委托给卫生部长

世界卫生组织发布报告,呼吁采取紧急行动应对慢性病和精神健康障碍,并要求作出高级别政治承诺。

世卫组织发布新版《国际疾病分类》

《国际疾病分类》是确定全球卫生趋势和统计数据的基础,其中含有约 55 000 个与损伤、疾病和死因有关的独特代码。它使卫生专业人员能够通过一种通用语言来交换世界各地的卫生信息。

世卫呼吁采取紧急行动防治非传染性疾病

世界卫生组织1日发布了一份关于全球非传染性疾病状况的最新报告,呼吁各国政府采取紧急行动,积极预防和控制心血管疾病、慢性呼吸系统疾病、癌症、糖尿病以及精神健康障碍等非传染性疾病。这份发表于国际著名学术期刊英国《柳叶刀》上的报告说,非传染性疾病已成为威胁人类健康的“头号杀手”,每年有4100万人死于癌症、糖尿病、肺病和心脏病,占全球死亡总人数的71%,其中1500万死亡病例年龄在30岁至70岁之间。

世卫组织公布全球前十位死亡原因,中国则略有不同,对付中国头号杀手需大下力气控制高血压

世卫组织(WHO)近日公布了最新的全球前十位死亡原因,其中非传染性疾病占六个。